Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Microbiol.

Sec. Antimicrobials, Resistance and Chemotherapy

Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1676135

This article is part of the Research TopicIntegrative Microbial and Chemical Genomics to Decipher Antibiotic Resistance Mechanisms and Developing Innovative Antimicrobial ApproachesView all 3 articles

Antibacterial Mechanism of Hyper-branched Poly-L-lysine against Methicillin-Resistant Staphylococcus aureus and Its Synergistic and Antagonistic Interactions with Conventional Antibiotics

Provisionally accepted
Yaoqin  WangYaoqin WangQiaoli  WuQiaoli Wu*Guofeng  MaoGuofeng MaoLulin  RaoLulin RaoMeichun  LiangMeichun LiangHe  SunHe Sun
  • Shaoxing People‘s Hospital, Zhejiang, China

The final, formatted version of the article will be published soon.

The global proliferation of multidrug-resistant pathogens, particularly Methicillin-resistant Staphylococcus aureus (MRSA), constitutes a severe threat to public health, rendering many conventional antibiotics obsolete. In the post-antibiotic era, where the pace of bacterial resistance evolution far exceeds that of new drug discovery, novel therapeutic strategies are urgently required. This study investigates the antibacterial potential of hyper-branched poly-L-lysine (HBPL), a synthetic antimicrobial polymer, against MRSA. We elucidate a multi-modal, physically disruptive mechanism of action initiated by electrostatic binding to the bacterial envelope, followed by rapid membrane permeabilization and cellular collapse, as visualized by electron and confocal microscopy. HBPL demonstrated potent, concentration-dependent bactericidal activity against clinical and standard MRSA strains, with a minimum inhibitory concentration (MIC) of 0.5 mg/mL and a minimum bactericidal concentration (MBC) of 1.0 mg/mL. Furthermore, HBPL inhibited biofilm formation by three MRSA strains (87%, 73%, and 81%) at a concentration of 1.0 mg/mL, which is a great advantage against the persistent and recalcitrant nature of biofilm-associated infections. Combination therapy studies using checkerboard assays revealed mechanistically dependent interactions. A profound synergistic effect (Fractional Inhibitory Concentration Index [FICI] ≤ 0.5) was observed with Levofloxacin, attributed to HBPL-mediated membrane permeabilization enhancing intracellular drug access. Conversely, antagonism (FICI > 4) was noted with Daptomycin, likely due to competitive binding at the bacterial membrane. These findings underscore the importance of rational drug pairing. While prolonged exposure induced stable, low-level resistance in MRSA, this was associated with adaptive cell envelope remodeling rather than target-site mutation. Collectively, this research establishes HBPL as a promising membrane-active agent and adjuvant therapy, capable of not only direct bactericidal action but also of restoring the efficacy of existing antibiotics against formidable pathogens like MRSA.

Keywords: Methicillin-resistant Staphylococcus aureus1, Hyper-branched poly-L-lysine2, Antibacterial activity3, antibacterial mechanism4, Fractional Inhibitory Concentration Index5

Received: 30 Jul 2025; Accepted: 22 Sep 2025.

Copyright: © 2025 Wang, Wu, Mao, Rao, Liang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qiaoli Wu, wuqiaoli2022@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.